"While I admit there were some wasted years under TM, since DOC took over things have been moving a lightning speed. We went from one construct in clinical development to 4 under his leadership, successfully completed a PII and put our lead construct in a PIII with special protocol assessment, which will vastly speed approval when the vaccine proves safe and effective."
MP, I respectfully disagree. Under Tom Moore ADXS had the vet construct in clinical trial and had already finished the cervical cancer India Phase 2 trial, whose positive results were the reason the GOG became interested in conducting another Phase 2, which O'Connor fortuitously stepped into. As far as your reference to "lightening speed" I hope you are joking. It has been around three years since O'Connor struck the India Biocon and Asia GlobalPharma deals and we have heard no update whatsoever on any clinical advancements on either of these fronts. Regarding Aratana, well, now the expectation for conditional approval is sometime in 2017, while the original communication was by the end of 2015 to beginning of 2016. Then there's the clinical hold, which was a serious setback that contributed to the stock price collapse and likely a significant reason why the Phase 3 SPA was not granted until literally a year O'Connor's original timeline communication . Most agree that our science is solid with encouraging data, which supports the case that the shorts are targeting a management team they know is ineffective and so greedy and mis-aligned that they always give shorts an out by actions that arguably are more in line with self-enrichment than shareholder interests. I think if we ever want to see fair value we first need to address the real problem at hand, that is removing O'Connor and appointing a CEO who is shareholder friendly.
News 
Market Data 
Discover 
AI
